Gene Editing · global
Silencing APOC3 with a Single Dose: Cellectis Plans Human Trial of Gene-Editing Therapy in China
HEAL-101 demonstrated gene editing and lipid lowering in two separate mouse models. Cellectis confirmed that preparations for the first human trial remain on track, with preliminary data expected in the second half of 2027. How long a single treatment lasts and whether it is safe will be key questions in the next stage.
If a single dose could lower excessively high triglycerides over the long term, the burden of treatment could change. Cellectis is exploring this possibility with its in vivo gene-editing therapy HEAL-101. In its third-quarter business update released in November, the company said preparations remain on track for a Phase 1 investigator-initiated trial in China for severe hypertriglyceridemia, with preliminary human data expected in the second half of 2027.
The update follows preclinical results the company presented in late October at the European Society of Gene and Cell Therapy (ESGCT) annual meeting; it does not mean the human trial has begun. The available evidence comes from human liver cell lines and mice. It supports continued development of the therapy but cannot yet establish how much benefit patients might receive.
HEAL-101 targets the APOC3 gene, which is associated with elevated triglycerides. It uses lipid nanoparticles that preferentially deliver to the liver to encapsulate messenger RNA encoding a TALE base editor, with the aim of permanently inactivating APOC3 after a single intravenous dose. In human liver cell lines, the company reported an average editing rate of approximately 90%, without generating DNA double-strand breaks at the target site. This result alone is insufficient to establish overall safety.
The animal data need to be considered separately. In mice with normal blood lipid levels and humanized livers, a single intravenous injection produced an average editing rate of approximately 65% in the human APOC3 gene, reaching up to 70%. This experiment primarily demonstrated the editor’s ability to modify its target after delivery into the body; it was not an efficacy test in a model of severe hyperlipidemia.
The lipid-lowering results came from a separate group of mice with high triglyceride levels carrying a human APOC3 transgene. The company reported a 67%±12% reduction in APOC3 and a 75%±11% reduction in triglycerides, expressed as means and standard deviations. The announcement’s summary also described the effect as a “76% reduction.” When these figures are presented together, they should be understood in terms of the means and variability reported in the detailed data, rather than taken to mean that every animal achieved the same reduction.
The location of delivery also has implications for risk. Cellectis said that, among the tissues analyzed, editing activity was observed in the liver, with no significant activity seen in other tissues. However, tissue distribution and editing at unintended sites are distinct safety questions; these results do not establish a complete absence of off-target editing. The announcement also did not provide full details on sample sizes, long-term follow-up or toxicology. At this stage, the findings remain company-reported preclinical data presented at a conference.
Next, human trials must examine questions that animal models cannot yet answer: what dose can balance activity and safety, how long the lipid-lowering effect lasts, and whether permanently modifying a gene carries long-term consequences. If the preliminary data are released as scheduled in the second half of 2027, they will provide a basis for an early assessment. Whether a single treatment can become a sustainable care option will require longer clinical follow-up.